Trial Profile
An open-label multi-center study of ATI-5923 for anticoagulation in patients with atrial fibrillation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2016
Price :
$35
*
At a glance
- Drugs Tecarfarin (Primary)
- Indications Stroke
- Focus Adverse reactions; Therapeutic Use
- Sponsors ARYx Therapeutics
- 10 Nov 2007 Status changed from recruiting to completed.
- 02 Mar 2007 New trial record.